ENDOSCOPY BASED TREATMENT OF PATIENTS PRESENTED WITH UPPER GASTRO-INTESTINAL BLEED
Not Applicable
- Conditions
- Health Condition 1: K318- Other specified diseases of stomach and duodenum
- Registration Number
- CTRI/2023/10/058739
- Lead Sponsor
- MMCSBY Scheme Govt of Rajasthan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients’ = 18 years of age who present with obvious or occult blood loss, after confirming GAVE as the source, by upper GI endoscopy
morphological features. All types of morphology of GAVE, irrespective of pattern will be included.
Exclusion Criteria
1.Patients with bleeding peptic ulcers, bleeding esophageal or gastric varices or any other active source of bleeding identified with the aid of EGD, other than GAVE.
2. Patients previously received endotherapy (APC or EBL) for GAVE eradication
3.Patients on anti-platelet or anticoagulant therapy.
4.Patients with Hemorrhagic blood diseases.
5.Patients with Lymphoproliferative disorders.
6.Patients with advanced malignancy.
7.Patients with hemorrhagic PHG
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is to identify obliteration of endoscopic visible <br/ ><br>GAVE lesions & number of treatment sessions needed for complete obliteration. <br/ ><br>Timepoint: Primary outcome is to identify obliteration of endoscopic visible <br/ ><br>GAVE lesions & number of treatment sessions needed for complete obliteration. <br/ ><br>
- Secondary Outcome Measures
Name Time Method Secondary outcomes are pre- & post-treatment haemoglobin values, absolute change in haemoglobin value, number of blood transfusions needed. All other quantitative & qualitative parameters in two separate groups will be considered secondaryTimepoint: Sessions will be performed every 3-4 weeks until complete <br/ ><br>eradication of GAVE lesions is achieved. Thereafter, all patients will <br/ ><br>be kept on a monthly follow up of their clinical & laboratory <br/ ><br>parameters for 6 months.